ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Immunotherapy"

  • Abstract Number: 116 • 2017 ACR/ARHP Annual Meeting

    Immunotherapy-Induced Rheumatic Disease: How Prepared Are Rheumatologists to Address This Emerging Condition?

    Laura Cappelli1,2, Cassandra Calabrese3, Leonard H. Calabrese3 and Clifton O. Bingham III4, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, 4Rheumatology, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Cancer immunotherapy targeting immune checkpoints represents a major advance in oncology, yet has been associated with immune-related adverse events (IRAEs) affecting many organ systems,…
  • Abstract Number: 850 • 2017 ACR/ARHP Annual Meeting

    Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System

    Xerxes Pundole, Mohsin Shah, Noha Abdel-Wahab and Maria Suarez-Almazor, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX

    Background/Purpose: Immune checkpoint inhibitors have become standard of care for many malignancies. Although these therapies are effective, they can activate the immune system resulting in…
  • Abstract Number: 1148 • 2017 ACR/ARHP Annual Meeting

    Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response

    Melanie H. Smith1 and Anne R. Bass2,3, 1Medicine, New York Presbyterian Hospital (Cornell), New York, NY, 2Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 3Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY

    Background/Purpose: Checkpoint inhibitor immunotherapy has fundamentally changed the treatment for an actively expanding list of cancers, however its use is associated with immune related adverse…
  • Abstract Number: 1156 • 2017 ACR/ARHP Annual Meeting

    Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data

    Cassandra Calabrese1, Elizabeth Kirchner1, Apostolos Kontzias1, Laura Wood2, Brian Rini2, Vamsidhar Velcheti2 and Leonard H. Calabrese1, 1Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, 2Hematology and Oncology, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: The new and emerging field of immune related adverse events (irAEs) from cancer immunotherapies presents many unanswered questions. The spectrum of irAEs is broad…
  • Abstract Number: 1173 • 2017 ACR/ARHP Annual Meeting

    Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort

    David Liew1,2,3, Jessica Leung1, Bonnia Liu1, Jonathan Cebon3,4, Albert Frauman2,3 and Russell Buchanan1, 1Department of Rheumatology, Austin Health, Melbourne, Australia, 2Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, 3Department of Medicine, University of Melbourne, Melbourne, Australia, 4Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia

    Background/Purpose: Immune checkpoint therapy with programmed cell death protein 1 (PD-1) inhibitors has led to significant survival benefits in the treatment of multiple cancers. This…
  • Abstract Number: 1462 • 2017 ACR/ARHP Annual Meeting

    Induction of Immune Tolerance through an Epitope-Specific Vaccine Induces Clinical Amelioration in Patients with Rheumatoid Arthritis

    Jin Hui Sherlynn Chan1, Theodorus van den Broek2, Jing Yao Leong1, Maura Rossetti3, Roberto Spreafico4 and Salvatore Albani1,5, 1SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, 2University Medical Center of Utrecht, Utrecht, Netherlands, 3University of California, Los Angeles, Los Angeles, CA, 4Synthetic Genomics, La Jolla, CA, 5KK Women's and Children's Hospital, Singapore, Singapore

    Background/Purpose: The manipulation of immune tolerance using immune checkpoints such as PD-1 is gaining progressive attraction in diseases such cancer where such manipulation would be…
  • Abstract Number: 1741 • 2017 ACR/ARHP Annual Meeting

    Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases

    Francois-Xavier Danlos1, Anne-Laure Voisin2, Valérie Dyevre3, Jean-Marie Michot1, Emilie Routier4, Laurent Taillade5, Stéphane Champiat1, Sandrine Aspeslagh1, Julien Haroche6, Laurence Albiges7, Christophe Massard1, Nicolas Girard8, Stéphane Dalle9, Benjamin Besse7, Salim Laghouati2, Jean-Charles Soria1, Christine Mateus4, Caroline Robert4, Emilie Lanoy3, Aurélien Marabelle1,10 and Olivier Lambotte11, 1Drug Development Department, Gustave Roussy Institut, Villejuif, France, 2Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, 3Service de biostatistique et d’épidémiologie, Gustave Roussy Institut, Villejuif, France, 4Department of dermatology, Gustave Roussy Institut, Villejuif, France, 5Department of medical oncology, Pitié Salpétrière Hospital, Paris, France, 6Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 7Department of medical oncology, Gustave Roussy Institut, Villejuif, France, 88. Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France, 9Department of dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France, 10Immunotherapy program, Gustave Roussy Institut, Villejuif, France, 11Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France

    Background/Purpose: Patients with auto-immune or inflammatory diseases (AID) treated by immune check-points inhibitors (ICI) are intrinsically susceptible to develop immune related adverse events (irAE). We…
  • Abstract Number: 1880 • 2017 ACR/ARHP Annual Meeting

    Cancer Immunotherapy in Patients with Preexisting Rheumatologic Disease: The Mayo Clinic Experience

    Michael Richter1, Olga Pinkston2, Lisa Kottschade3, Heidi Finnes3, Svetomir N. Markovic4 and Uma Thanarajasingam5, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic Florida, Jacksonville, FL, 3Oncology, Mayo Clinic, Rochester, MN, 4Department of Medicine and Oncology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and…
  • Abstract Number: 2119 • 2017 ACR/ARHP Annual Meeting

    Rheumatological Immune Related Adverse Events in Malignancy Patients Treated with Anti-Programmed Cell Death (PD) 1 Antibodies

    Emma Mitchell1, Peter Lau2, Chloe Khoo2, Kortnye Smith2, Benjamin Brady2, Mark Shackleton2, Grant McArthur2, Ian Wicks1,3,4 and Shahneen Sandhu2, 1Rheumatology, Royal Melbourne Hospital, Melbourne, Australia, 2Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, 3Medicine, University of Melbourne, Melbourne, Australia, 4Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia

    Background/Purpose: Immune checkpoint inhibitors (ICIs), including anti-programmed cell death 1 (anti-PD 1) antibodies, are established therapies for advanced malignancies, including melanoma, and non-small cell lung…
  • Abstract Number: 2155 • 2017 ACR/ARHP Annual Meeting

    Myositis As a Complication of Checkpoint Blockade at a Comprehensive Cancer Center

    Mohsin Shah1, Jean Tayar1, Noha Abdel-Wahab1,2 and Maria Suarez-Almazor1, 1Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, 2Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt

    Background/Purpose: Immune checkpoint inhibitor therapy (ICI) has surfaced as a successful and robust treatment option in the fight to end cancer. As we gain more…
  • Abstract Number: 2702 • 2017 ACR/ARHP Annual Meeting

    Tissue-Invasive T Cells in Rheumatoid Arthritis

    Cornelia M. Weyand1, Yi Shen2, Yinyin Li1, Eric L. Matteson3, Stuart Goodman4 and Jorg Goronzy5, 1Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, 2Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Orthopaedic Surgery, Stanford Medical Center Outpatient Clinic, Redwood City, CA, 5Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: A key pathogenic event in rheumatoid arthritis (RA) is the formation of lasting lymphoid microstructures in the synovial tissue. It requires the transmigration of…
  • Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting

    Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

    Jens Humrich1, Caroline von Spee-Mayer2, Elise Siegert3, Angelika Rose2, Martina Bertolo4, Philipp Enghard5, Falk Hiepe6, Tobias Alexander7, Eugen Feist8, Andreas Radbruch9, Gerd R. Burmester10 and Gabriela Riemekasten11, 1Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, 2Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, 4Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, 5Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, 6Charité – Universitätsmedizin, Berlin, Germany, 7Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 8Charité-Universitätsmedizin Berlin, Berlin, Germany, 9Deutsches Rheumaforschungszentrum, Berlin, Germany, 10Charité – University Medicine Berlin, Berlin, Germany, 11Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

    Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • Abstract Number: 1339 • 2016 ACR/ARHP Annual Meeting

    Rheumatic Immune Related Adverse Events of Checkpoint Therapy for Cancer: Case Series of a New Nosologic Entity

    Cassandra Calabrese1, Apostolos Kontzias1, Vamsidhar Velcheti2 and Leonard H. Calabrese1, 1Rheumatic & Immunologic Disease, Cleveland Clinic, Cleveland, OH, 2Hematology and Oncology, Cleveland Clinic, Cleveland, OH

    Background/Purpose:   The introduction of immunotherapy with biologic agents targeting immunologic checkpoints (i.e. CTLA4 and PD-1/PDL-1) have yielded impressive gains for cancer patients. These agents…
  • Abstract Number: 2934 • 2016 ACR/ARHP Annual Meeting

    Clinical Assessment of the Monoclonal Anitbody, PRX003, a Potential Novel Treatment for Th17-Mediated Inflammatory Disease

    Gene G. Kinney1, Kenneth Flanagan1, Michael Skov1, Ronald Goldblum2, Sue Griffith3, Robin M. Barbour1, Wagner Zago1, Ted Yednock1, Martin Koller1 and Dan Ness1, 1Prothena Biosciences Inc, South San Francisco, CA, 2Carlsbad Pharmaceutical Consulting, Inc., Carlsbad, CA, 3ClinPharma Services, Inc, San Diego, CA

    Background/Purpose: Melanoma cell adhesion molecule (MCAM; CD146) is expressed on the surface of Th17 cells, which have the capacity to produce IL-17 and a multitude…
  • Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting

    Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE

    Jens Y. Humrich1, Caroline von Spee-Mayer1, Elise Siegert1, Angelika Rose1, Tobias Alexander2, Falk Hiepe1, Andreas Radbruch3, Gerd Burmester4 and Gabriela Riemekasten1, 1Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 4Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology